Sridhar, Vikas S. http://orcid.org/0000-0001-7947-1822
Limonte, Christine P.
Groop, Per-Henrik
Heerspink, Hiddo J. L.
Pratley, Richard E.
Rossing, Peter
Skyler, Jay S.
Cherney, David Z. I.
Article History
Received: 26 April 2023
Accepted: 21 July 2023
First Online: 6 October 2023
Funding
: VSS is supported by a Department of Medicine Eliot Phillipson Clinician-Scientist Training Program, a Banting and Best Diabetes Centre Postdoctoral Fellowship at the University of Toronto and a Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award. CPL is supported by an American Kidney Fund’s Clinical Scientist in Nephrology Award. DZIC is supported by a Department of Medicine, University of Toronto Merit Award and receives support from the CIHR, Diabetes Canada and the Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research. DZIC is also the recipient of a 5 year CIHR–Kidney Foundation of Canada Team Grant Award. PR is supported by a Novo Nordisk Foundation grant (NNF22OC0077730; ‘Multifactorial intervention to reduce cardiorenal disease in type 1 diabetes – a prospective, randomised, open, multicenter study – the Steno 1 study’). JSS is supported by the Diabetes Research Institute Foundation.
: VSS has received conference travel support from Merck. DZIC has received honoraria from Boehringer Ingelheim–Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi Tanabe, AbbVie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago and Novo Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim–Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL Behring and Novo Nordisk. PR has received the following: consultancy and/or speaking fees (to his institution) from AbbVie, Abbott, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gilead, Novo Nordisk and Sanofi-Aventis, and research grants from AstraZeneca, Bayer and Novo Nordisk. REP has received consulting fees from Bayer, Corcept Therapeutics, Dexcom, Hanmi Pharmaceutical, Merck, Novo Nordisk, Pfizer, Sanofi, Scohia Pharma and Sun Pharmaceutical Industries, and grants/research support from Hanmi Pharmaceutical, Janssen, Metavention, Novo Nordisk, Poxel and Sanofi. All funds are paid directly to REP’s employer, AdventHealth, a non-profit organisation that supports education and research. JSS has been an advisor to 4Immune, Adocia, Altheia, Arecor, AstraZeneca, Avotres, Bayer, COUR, Cue Biopharma, Dance Biopharm/Aerami, Diasome, Enthera, Imcyse, Immunomolecular Therapeutics, Kriya, Novo Nordisk, Oramed, Orgenesis, Precigen/ActoBiotics, Provention Bio, Sanofi, Signos, Vertex and Viacyte. He is a member of the Board of Directors of Dexcom and Applied Therapeutics. He is Chair of the Strategic Advisory Board of the EU INNODIA consortium. P-HG has received lecture fees from Astellas, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi and Sciarc. He is an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Nestlé, Novartis, Novo Nordisk and Sanofi. CPL declares that there are no relationships or activities that might bias, or be perceived to bias, their work.
: VSS, CPL, P-HG, HJLH, REP, PR, JSS and DZIC conceived and designed the manuscript; VSS, CPL and DZIC drafted the paper; VSS, CPL, P-HG, HJLH, REP, PR, JSS and DZIC performed critical revision. All authors approved the final version to be published.
Free to read: This content has been made available to all.